AML in the molecular age

In this issue, we have covered the new era in acute myeloid leukemia (AML). Molecular abnormalities have become increasingly important, not only in prognostication but also management of AML. The rationale of targeted therapies, hypomethylating agents were reviewed. While we are emphasizing management of AML regarding molecular abnormalities, we also tackled treatment differences regarding age, and disease status. Allogeneic hematopoietic cell transplantation has been the most important means to cure AML; however, in this issue we focused on alternative donor sources that has becoming highly important. In the same regard, T-cell depletion and its pros and cons were reviewed. Lastly, what is the place of radiology for diagnosis of central nervous system leukemia was discussed.
[Basel: 2018]

Compartir: